Chief executive of Alkermes Richard Pops in their Dublin offices: the firm’s  net loss  jumped to $77.4 million from $30.7 million. Photograph: Aidan Crawley

Biopharma group Alkermes has reported a sharp increase in its net loss in the first quarter on the back of increased investment in its late-stage pipe(...)

Genzyme’s 24-hour resuscitation marathon was part of its wellbeing programme
Fit for work in mind and body

Looking after the mental health and wellbeing of employees is becoming a priority for many companies. “Many employers now help staff with everything f(...)

At Britvic’s employee conference,  the warehouse operative and customer management teams’ ideas included building  pyramids of products
The top 10 secret weapons

1 Ask Me Anything (AMAs) – Riot Games: Gathering open feedback is vital to the culture at Riot Games, developer and publisher of the online game Leag(...)

Members of the  Save Roscommon campaign.

On a map, the 30 sq km of Roscommon that is being proposed as an addition to Westmeath looks like a square wedge marked off by one of those colonial l(...)

Richard Pops, chief executive  of Alkermes.  Photograph: Aidan Crawley/The Irish Times

Irish drugmaker Alkermes fell Tuesday after receiving US regulatory approval for a schizophrenia treatment, and an analyst predicted that uptake of th(...)

Alkermes president Shane Cooke. Photograph: Kate Geraghty/ The Irish Times

Alkermes, the Irish drug company specialising in drugs for conditions affecting the central nervous system has upgraded its forecasts for the full yea(...)

Richard Pops, chief executive  of Alkermes at their Dublin offices. Photograph: Aidan Crawley

Revenue at Irish drug group Alkermes jumped almost 24 per cent in the first three months of the year, to $161.2 million, ahead of analyst expectations(...)

Richard Pops, chief executive  of Alkermes in their Dublin offices. Photograph: Aidan Crawley

Biopharma group Alkermes has reported fourth-quarter earnings and revenues that beat expectations. However, it fell to a full-year loss on generally (...)

Civitas is developing an inhaled form of the drug levadopa that is currently used by Parkinson’s patients in tablet form.

Irish private equity group Fountain Healthcare is one of the big winners following the sale of a company that has developed a experimental therapy fo(...)

Walgreens  pharmacy chain announced a  deal to acquire full control of Switzerland-based Alliance Boots – but without an inversion that could have saved the company billions of dollars in taxes. Photograph: Reuters

Billions of dollars were wiped off the value of European healthcare companies yesterday after the Obama administration threatened action to halt the w(...)